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Background: Porcine circovirus type 2 (PCV2) is associated with post-weaning multisystemic wasting syndrome
(PMWS), an emerging swine disease that causes progressive weight loss, dyspnea, tachypnea, anemia, jaundice, and
diarrhea in piglets. Although baculovirus is an enveloped virus that infects insects in nature, it has emerged as a
vaccine vector, and we used it to develop a novel candidate vaccine for a preventive or therapeutic strategy to
control PCV2 infections.
Methods: Immunoblotting analysis of recombinant baculovirus and immunofluorescent staining of baculovirus-infected
cells were followed using anti-ORF2 monoclonal antibodies. The BALB/c mice were immunized intramuscularly with this
baculovirus. The titers of antibodies were mensurated with a Cap-protein-specific enzyme-linked immunosorbent assay
(ELISA) and a serum neutralization assay. The IFN-γ response in splenocytes harvested from immunized mice was
measured by ELISA. Student's t-test was used to compare immune responses of different groups.
Results: In this study, we successfully constructed a dual-expression-system-based recombinant baculovirus BV-GD-ORF2
, which can display the PCV2 capsid (Cap) protein and VSV-G protein on the viral envelope and also expressing Cap
protein on transduced mammalian cells, thereby functioning as both a subunit and a DNA vaccine. After infection, the
Cap protein was expressed and displayed on the viral surface, as demonstrated with an indirect fluorescence assay and
immunoblotting. The vaccination of mice with recombinant baculovirus BV-GD-ORF2 successfully induced robust
Cap-protein-specific humoral and cellular immune responses.
Conclusions: Our findings collectively demonstrate that the recombinant baculovirus BV-GD-ORF2 is a potential vaccine
against PCV2 infections.
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Porcine circovirus type 2 (PCV2), a member of the family
Circoviridae, is recognized as the causative agent of the
various clinical manifestations of PCV-associated diseases
(PCVAD), although other factors influence the severity of
the clinical symptoms [1]. To combat the growing problems* Correspondence: fanhy@scau.edu.cn
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reproduction in any medium, provided the orassociated with PCV2-associated disease, several commer-
cial PCV2 vaccines have been developed and been shown to
provide some degree of protection against PCV2 infection
[2,3]. In the present study, a new approach to the prevention
and control PCV2 was explored using a baculovirus dual
expression system to express the capsid (Cap) protein of
PCV2 as a subunit vaccine and a DNA vaccine.
The baculovirus Autographa californica multiple nu-
clear polyhedrosis virus (AcMNPV) has been used trad-
itionally as an excellent tool to overexpress recombinant
proteins in insect cells [4-6]. Because the baculovirus
can enter mammalian cells and mediate the expressionThis is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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malian cells [7], baculoviral vectors have been exploited
as versatile vaccine vehicles to produce candidate vac-
cines against various pathogens [8-10]. It has also been
reported that a pseudotype baculovirus displaying the
glycoprotein of vesicular stomatitis virus (VSV-G) on its
envelope can extend the host range of the baculovirus
and enhance its resistance to inactivation by animal
serum complement [11-13].
Recently, AcMNPV has been further engineered for
use as a new eukaryotic display system to express ex-
ogenous peptides on the surface of the viral envelope.
This display strategy relies on thegp64 protein, which is
the major envelope protein of the baculoviruses, which
has an amino-terminal signal peptide (SP), a mature trans-
membrane domain (TM) and a cytoplasmic tail domain
(CTD). For the surface display of exogenous peptides, a
heterologous peptide was inserted between the SP and
mature domain of gp64. After its expression with the na-
tive gp64, the fusion protein is translocated to the plasma
membrane and incorporated into the baculoviral envelope.
This method has been extended to develop pseudotyped
baculoviruses as a potential vaccine delivery platform. Sev-
eral research groups have demonstrated that direct vaccin-
ation with pseudotyped baculoviruses can induce high
titers of antigen-specific antibodies [14-16].
Based on the characteristics of the baculoviruses as a
gene delivery system and surface display system together, a
dual-expression-system-based recombinant baculovirus
BV-GD-ORF2 was constructed in this study, which can
display the PCV2 Cap protein and the VSV-G protein on
the viral envelope and expresses the Cap protein when it is
used to transduce mammalian cells. The first objective of
this study was to effectively display the functional Cap pro-
tein on the baculoviral envelope, hoping that the Cap pro-
tein would retain its superior immunogenicity after in vivo
immunization. Our second objective was to efficiently ex-
press the Cap protein in transduced mammalian cells. The
third objective was to display the VSV-G protein on the
viral envelope to boost the baculovirus resistance to com-
plement. The potential utility of BV-GD-ORF2 as a vaccine
was evaluated in a mouse model. Robust humoral and cel-
lular immune responses were successfully induced in mice
immunized with the recombinant baculovirus BV-GD-
ORF2. These results suggest that a PCV2 vaccine based on
the baculovirus dual expression system can be used as an
alternative strategy to protect against PCV2 infection. To
our knowledge, this is the first study to establish a PCV2
vaccine based on the baculovirus dual expression system.
Results
Construction of the baculovirus dual expression system
The recombinant baculovirus BV-GD-ORF2 was con-
structed as described in the Methods (Figure 1). Theinfection of Sf9 cells with BV-GD-ORF2 caused in exten-
sive cell-cell fusion (Figure 2). This phenotype is attribut-
able to the very high expression level of VSV-G protein,
which has membrane-fusion activity, under the control of
the polyhedrin promoter (PPH).
To investigate whether the Cap protein was displayed
on the membrane of BV-GD-ORF2, the purified viral
particles were analyzed with immunoblotting with an
anti-ORF2 monoclonal antibody. A protein of an approxi-
mately 75 kDa protein (of the predicted size) was presented
in the lanes loaded with the recombinant baculovirus BV-
GD-ORF2 or with BV-GD-ORF2-infected Sf9 cells, but not
in lanes containing pellets of viral nucleocapsids only or
in those lanes loaded with AcMNPV wild-type (AcMNPV-
WT) infected Sf9 cells (Figure 3). Our observations in-
dicated that the presence of both VSV-G and PCV2 Cap
protein does not significantly reduce the displaying effi-
ciency of Cap protein on baculovirus membrane.
To test the ability of BV-GD-ORF2 to express the
Cap protein in mammalian cells, PK-15 cells were trans-
duced with BV-GD-ORF2 and AcMNPV-WT. Distinct
fluorescent signals were detected in the BV-GD-ORF2-
transduced cells but not in the cells transduced with
AcMNPV-WT (Figure 4). These results demonstrated that
BV-GD-ORF2 not only displays the PCV2 Cap protein
on the viral envelope but also expresses it in mam-
malian cells.
Humoral immune responses in mice immunized with BV-
GD-ORF2
To determine whether BV-GD-ORF2 can induce PCV2-
specific immune responses in vivo after direct immunization,
BALB/c mice were immunized intramuscularly with BV-
GD-ORF2, pc-ORF2, AcMNPV-WT or phosphate-buffered
saline (PBS). Cap-protein-specific antibodies and neutral-
izing antibodies were determined 3, 6, and 9 weeks after
the primary immunization.
As shown in Figure 5a, 3 weeks after the primary
immunization, Cap-specific antibodies were detected in
all the mice immunized with BV-GD-ORF2 or pc-ORF2.
Following the booster immunization, the mean antibody
titers increased rapidly in the mice treated with BV-
Dual-ORF2 or pc-ORF2, and there was a significant differ-
ence between the two groups at 6 weeks (P < 0.01) and 9
weeks (P < 0.01) after the primary immunization.
Serum samples were evaluated for their capacity to
neutralize PCV2 strain GD-68 in a serum neutralization
assays. As shown in Figure 5b, during the experimental
period, mice immunized with the BV-GD-ORF2 devel-
oped significantly higher PCV2-specific neutralizing anti-
body titers than mice injected with pc-ORF2 (P <0.01),
and the average neutralizing antibody titers in the mice
vaccinated with BV-GD-ORF2 was up to 1:25.6 at 6 weeks
after the primary immunization. As expected, none of the
Figure 1 Schematic representation of the structure ofBV-GD-ORF2. The ORF2 gene cassette consists of the gp64 signal sequence (SP), the
ORF2 gene (ORF214–234) fused to the N-terminus of the AcMNPV major envelope protein gp64 gene (gp6425–517), and the poly(A) sequence,
which was driven by a dual promoter containing the CMV immediate-early enhancer/promoter (pCMV-IE) and the polyhedrin promoter (PPH).
The VSV-G expression cassette was driven by the p10 promoter (PP10). ORF214–234:ORF2 corresponding to amino acids 14–234, but lacking the
N-terminal nuclear localization signal peptide of the capsid protein of PCV2. Gp6425–517: gp64 corresponding to amino acids 25–517.VSV/G: the
glycoprotein of vesicular stomatitis virus.
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produced detectable Cap-protein-specific antibodies or
neutralizing antibodies throughout the whole experimen-
tal period.
Cellular immune response in mice immunized with
BV-GD-ORF2
To characterize the cell-mediated immune responses in
mice immunized with BV-GD-ORF2, splenocytes were
isolated from the immunized mice at 6 weeks after the
primary immunization and interferon γ (IFN-γ) produc-
tion in splenocytes restimulated with the recombinant
Cap protein was measured with an ELISA. As shown in
Figure 6, mean IFN-γ levels of 621 pg/ml or 112 pg/ml
were detected in mice inoculated with 1× 109 PFU of
BV-GD-ORF2 or pc-ORF2, respectively, and the differ-
ence between the two groups was significant (P < 0.01).
Splenocytes from mice immunized with AcMNPV-WT
also showed a relatively high nonspecific IFN-γ response
(189 pg/ml).
Because nearly all swine herds are seropositive for
PCV2 and there are insufficient numbers of specific-
pathogen-free swine, and because experimentation with
swine is expensive, our results were obtained with animalsFigure 2 Characterization of BV-GD-ORF2-infected Sf9 cells. Syncytium
white arrow (a), but not in the mock-infected Sf9 cells (b). The images werother than swine. Therefore, future studies should include
data from swine if we are to completely understand the
potential utility of candidate PCV2 vaccines based on the
dual expression system of recombinant baculoviruses dis-
playing immunogens.
Discussion
Porcine circovirus 2 is the principal infectious agent im-
plicated in the development of PMWS [17,18] and has
also been associated with many other conditions such as
porcine dermatitis and nephropathy syndrome (PDNS)
and congenital tremors (CT), which are now collectively
known as PCVAD [19]. Despite the use of preventive
measures involving swine housing and herd manage-
ment, high PCV2 seroprevalence and PMWS are found
in many herds. The prevention of this disease maybe
possible if vaccination-induced immunity can be devel-
oped in piglets before the time at which waning mater-
nal immunity makes the animals susceptible to PCV2
infection [20]. Although several commercial vaccines
have been developed to control PCV2 infections, there
are potential safety problems associated with killed vac-
cines, including their incomplete inactivation and an in-
creased risk of allergic reactions arising from the largeformation in Sf9 cells infected with BV-GD-ORF2 as indicated by the
e captured at 72 h posttransfection. Original magnification, ×100.
Figure 3 Immunoblotting analysis of recombinant AcMNPV
particles using anti-ORF2 monoclonal antibodies. Sf9 cells
infected with BV-GD-ORF2 (lanes 1); Sf9cells infected with AcMNPV-WT
(lanes 2); complete BV-GD-ORF2 virions (lanes 3); and purified
nucleocapsids from BV-GD-ORF2 virions treated with Triton X-100
(lanes 4). All were treated with lysis buffer and subjected
toimmunoblotting. Expression of the ORF2–gp64fusion protein
was examined.
Figure 5 Antibody responses in mice immunized with of BV-
GD-ORF2. Mice were immunized intramuscularly with BV-GD-ORF,
pc-ORF2, AcMNPV-WT or PBS. An identical booster immunization
was given 3 weeks later. Serum was obtained at 3, 6, and 9 weeks.
Antibody levels were analyzed with a Cap-protein-specific ELISA
(a) and a serum neutralization assay (b). All data are means ± SD.
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make vaccination far more available for livestock, whereas
genetically engineered vaccines, such as baculovirus-based
vaccine, especially for the farms in developed countries.
Thus, the development of an effective and affordable vac-
cine against PCV2 infection is an acceptable strategy for
the prophylaxis of PMWS.
In this study, the dual-expression-system-based recombin-
ant baculovirus BV-GD-ORF2 has been developed, which
possesses two gene cassettes: PP10 promoter-controlled
VSV-G expression cassette and CMV immediate-early en-
hancer (CMV-IE) and PPH promoters-controlled PCV2
ORF2 expression cassette. We investigated the efficacy of
BV-GD-ORF2 as a vaccine against PCV2. Our results clearly
showed that immunization with BV-GD-ORF2induced ro-
bust humoral and cellular immune responses in a mouseFigure 4 Immunofluorescent staining of BV-GD-ORF2-infected cells. P
an MOI of 10, respectively. At 48 h posttransfection, the cells were fixed with
assay with mouse monoclonal antibody directed against ORF2. The bound an
with fluorescence microscopy (green). Original magnification, ×100.model, indicating that BV-GD-ORF2 has value as a candi-
date vaccine to prevent and control PCV2.
Previous studies have shown that the PCV2-neutralizing
antibodies were correlated, to some degree, with the effi-
cacy of protection against PCV2. In this study, miceK-15 cells were transfected with BV-GD-ORF2 (a) or AcMNPV-WT (b) at
absolute methanol, and processed for an indirect immunofluorescence
tibodies were detected with FITC-labeled anti-mouse IgG and observed
Figure 6 The IFN-γ response in splenocytes harvested from
immunized mice was measured by ELISA. Mice were immunized
as in Figure 5. Splenocytes were isolated at 6 weeks after the
primary immunization and stimulated with or without purified Cap
protein in vitro for a defined time. The IFN-γ levels in the
supernatant were analyzed with an ELISA. Data are means ± SD.
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higher PCV2-specific neutralizing antibody titers than did
those immunized with pc-ORF2, probably because of the
nature of the vaccine form. BV-GD-ORF2 is capable of
the surface-display of the PCV2 Cap protein on the viral
envelope and expresses it on transduced mammalian cells,
so it plays dual roles as a subunit vaccine and a DNA vac-
cine, whereas pc-ORF2 only expresses Cap protein and
functions as a DNA vaccine. In contrast, VSVG is dis-
played on the envelope of the pseudotyped baculovirus.
The VSVG-modified virus not only prevents attack by the
complement system in the mammalian serum, but also
the efficiency of gene transfer into mammalian cells
in vivo [21]. The Cap protein displayed on the envelope of
BV-GD-ORF2 allows it to engage antigen-presenting cells
(APCs) and activate the ORF2-specific immune reactions
via the major histocompatibility II (MHC-II)-mediated
antigen-presentation pathway, thus leading to more po-
tent immune responses [22]. Moreover, unlike the DNA
vaccine, the baculovirus can directly transduce the APCs
[23,24] resident in the muscle tissues and thus present
antigen more efficiently to dendritic cells (DCs), which are
the most important APCs [25].
The protective immunity elicited by PCV2 vaccines is
considered to be primarily mediated by the humoral re-
sponse, although few data are available that describe the
role of cell-mediated immunity in protection against
PCV2. Previous studies have suggested that high levels
of IFN-γ have a deleterious effect on protective immunity
[26]. However, Shen et al. recently reported that protective
immunity against PCV2 in mice was mediated by Cap-
specific CD8+ cells and a seroneutralization response [27].
Fort et al. also demonstrated that PCV2-specific cellular
responses in pigs contributed, together with neutralizing
antibodies, to viral clearance [2]. A previous study also
showed that immunization with adjuvant-free baculovirusdisplaying the rodent malaria Plasmodium berghei circum-
sporozoite protein on its envelope induced high levels of
antibodies and IFN-γ-secreting cells, and protected 60%
of mice against sporozoite challenge [28]. In this study,
we observed a significantly enhanced cell-mediated im-
mune response in mice immunized with BV-GD-ORF2
compared with that of mice immunized with pc-ORF2. A
higher background of nonspecific IFN-γ production in
splenocytes harvested from the baculovirus-injected mice
was also observed. This might be because gp64, the
baculovirus envelope protein, recognizes the TLR9 mol-
ecule and thus activates the innate immune response [29].
This is consistent with the results of a previous study in
which intranasal immunization with WT baculovirus
alone provided sufficient protection from lethal challenge
with the H1N1 influenza virus [8].
At present, there are at least four commercially available
PCV2 vaccines, including subunit vaccines that express
the Cap protein from baculovirus, inactivated PCV2, and
a PCV1/PCV2 chimeric vaccine [27]. However, the propa-
gation of PCV2 or the production of a recombinant Cap
protein in expression systems designed for vaccine pro-
duction is a time-consuming, expensive and laborious
process [30]. In contrast, the baculovirus dual expression
system allows the rapid generation of recombinant baculo-
viruses, and high titers (>109 PFU/ml) can be produced
easily. In particular, the inability of baculoviruses to repli-
cate in mammalian cells makes them attractive candidate
vectors for transgenic expression studies if they are engi-
neered to contain suitable expression cassettes [31]. Con-
sidering the safety, the cost-effectiveness, and the simple
scale-up required to produce high-titer recombinant bacu-
loviruses, the baculovirus dual expression system is a
promising method of vaccine development, superior to
other viral systems.
The baculovirus vector also has a large genome, which
allows the insertion of large foreign DNA fragments or
the construction of multivalent vaccines possible. In a
further study, we plan to improve the immunization effi-
ciency of this system by the tandem expression of mul-
tiple Cap proteins to produce multivalent vaccines, and
display a single-chain antibody fragment specific for
some pathogens or ligand-directed specific targeting of
baculovirus to increase the tropism in virus-infected
mammalian cells. We are also ready to co-express the
Cap protein and other immunogenic proteins of some
important pathogens, such as the GP5 and M proteins
of porcine reproductive and respiratory syndrome virus
(PRRSV), in order to develop a potential divalent candi-
date vaccine against PRRSV and PCV2 infections.
In summary, this study demonstrates that the vaccine
BV-GD-ORF2, based on the baculovirus dual expression
system, can be used as an alternative strategy to prevent
and control PCV2. Although mice were used as the
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munogenic efficacy of the PCV2 vaccine [32,33], other
experiments are required to determine the immunogen-
icity and protective effect of this recombinant baculo-
virus in pigs [34].
Conclusions
A dual-expression-system-based recombinant baculo-
virus BV-GD-ORF2 displays the PCV2 Cap protein with
the baculovirus envelope protein gp64 TM and CTD on
the viral envelope and also expresses it on transduced
mammalian cells, thereby functioning as both a subunit
vaccine and a DNA vaccine. The vaccination of mice with
BV-GD-ORF2 successfully induced robust Cap-protein-
specific humoral and cellular responses. Collectively, our
results indicate that the recombinant baculovirus BV-GD-
ORF2 is a potential vaccine against PCV2 infection.
Methods
Cell lines
The porcine kidney cell line (PK-15) free of PCV1 con-
tamination (ATCC CCL 33) was maintained in Dulbecco’s
modified Eagle’s medium (DMEM, Invitrogen, Carlsbad,
CA, USA), supplemented with 10% (v/v) heat-inactivated
fetal bovine serum (FBS, Invitrogen), 100 g/mL of strepto-
mycin and 100 IU/mL of penicillin. Spodoptera frugiperda
cells (Sf9) were used to propagate the WTand recombinant
baculoviruses and were cultured in Grace’s insect media
(Invitrogen) supplemented with 10% heat-inactivated FBS
at 27°C. PCV2 strain GD-68 used in this study was origin-
ally isolated from a pig with naturally occurring PMWS.
Construction of recombinant baculovirus
To generate the recombinant baculovirus BV-GD-ORF2,
VSV–G cDNA with the β–globin terminator was PCR
amplified from pVSV–G (Clontech, Mountain View, CA,
USA) and subcloned into the shuttle vector pFastBac™-
Dual plasmid (Invitrogen). The ORF2 gene lacking the
N–terminal nuclear localization signal peptide was ampli-
fied from PCV2 genomic DNA by PCR and inserted be-
tween the sequences encoding the gp64 signal peptide
and the transmembrane domain of pBACsurf–1 vec-
tor (Novagen, Madison, WI, USA). To construct pCMV–
surf–ORF2, a 2.1-kb fragment of the surf–ORF2 fusion
gene was excised from psurf–ORF2 by digestion with
NheI and HindIII, and inserted into the NheI/HindIII
sites in the pcDNA3.1(+) vector (Invitrogen, Carlsbad, CA).
A cassette comprised of CMV-IE promoter and the surf-
ORF2 fusion gene was amplified by PCR and subcloned
into plasmid pFastBac™ Dual after SalI/HindIII treatment
to generate pBac-GD-ORF2. The resultant pBac-GD-ORF2
plasmid thus contained the PCV2 ORF2 gene driven by the
CMV-IE + PPH promoters and the VSV–G gene driven by
the PP10 promoter.All procedures for the production of recombinant
baculovirus BV-GD-ORF2 were performed according to
the manufacturer's manual of Bac-to-Bac® Baculovirus
Expression System (Invitrogen). Viral particles were puri-
fied with two rounds of sucrose gradient ultracentrifuga-
tion following standard protocols [35], and infectious
titers were determined with the BD BacPAK™ Baculovirus
Rapid Titer Kit (Clontech).
Immunoblotting analysis
To investigate whether ORF2 is displayed on the envelop
of BV-GD-ORF2, the purified virions were treated with
1% Triton X-100 to disrupt the virion structure, and
then the viral nucleocapsids were collected by ultracen-
trifugation. The viral nucleocapsids, purified recombin-
ant baculovirus and infected cell lysates in PBS (pH 7.4)
were then mixed with lysis buffer (50 mM Tris–HCl
[pH 6.8], 0.1 M dithiothreitol, 2% sodium dodecyl sulfate
[SDS], and 10% glycerol) and resolved by SDS-12% poly-
acrylamide gel electrophoresis. Fractions containing the
purified baculovirus were then transferred onto nitrocel-
lulose membrane. Immunoblotting was performed as
previously described [9] with an anti-ORF2 monoclonal
antibody (Ingenasa Inc., Spain).
Immunofluorescence assay
PK-15 cells were seeded at a concentration of 2.5 × 105
cells/well into six-well tissue culture plates (Nunc, Rochester,
NJ, USA) and transduced with purified baculovirus parti-
cles at a multiplicity of infection (MOI) of 10. After in-
cubation for 48 h, the cells were fixed for 15 min with
absolute methanol (100%) and incubated with anti-ORF2
monoclonal antibody (Ingenasa Inc.), and then with
fluorescein-isothiocyanate (FITC)-conjugated rabbit anti-
porcine IgG (Sigma, St. Louis, MO, USA). Fluorescent
images were examined under an inverted fluorescence
microscope (Olympus IX70, Japan).
Mouse immunization schedule
Six-week-old female BALB/c mice were purchased from
Southern Medicine University, Guangzhou, China, and
cared for according to the Chinese Guidelines for
Laboratory Animals in the microisolator units at Southern
China Agricultural University. Three groups of mice (eight
per group) were vaccinated intramuscularly twice at 3-
week intervals with 109 PFU of BV-GD-ORF2, 109 PFU of
AcMNPV wild-type (AcMNPV-WT) or 100 μg of pc-
ORF2.A fourth group was injected with 100 μl of PBS
and used as the control group. Serum samples were col-
lected 3, 6, and 9 weeks after the primary inoculation to
detect the Cap protein-specific ELISA antibodies and neu-
tralizing antibodies against PCV2. Six weeks after the pri-
mary immunization, three mice from each group were
killed for a cell-mediated immune assay.
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An endpoint ELISA and serum neutralization assay were
performed as previously described [9].
IFN-γ release assays
Mouse splenocytes were prepared as previously described
(Fan et al., 2008), and incubated in 24-well flat-bottomed
plates (1 × 106 cells/well) in the presence of Cap protein
(20 μg/ml). After incubation for 72 h, the culture super-
natant was harvested and the presence of IFN-γ was mea-
sured with a commercially available mouse IFN-γ ELISA
kit (Biosourse, USA) according to the manufacturer's in-
structions. The concentrations of mouse IFN-γ in the
samples were determined from a standard curve.
Statistical analysis
Student's t-test was used to compare the humoral and
cell-mediated immune responses of the different groups.
P values of <0.05 were considered statistically significant.
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